Liestal, Switzerland, 21 November 2025: Curatis Holding AG (SIX: CURN) today announces that it has entered into a definitive agreement for a private placement of a convertible instrument of CHF 1.2 million with a strategic Swiss investor.

Under the terms of the agreement, the investor will subscribe for a convertible instrument convertible into shares of Curatis Holding AG. The shares are expected to be delivered from Curatis’ conditional capital. The instrument has been issued at prevailing market conditions. The transaction is expected to close within the next few days, subject to customary conditions.

First and foremost, the proceeds will allow to accelerate the development of the Company’s late stage clinical lead product candidate corticorelin.